Chapter 7 Chapter 5 Genes—The Wealth Plan

Human beings are the final realization of the genome project, not just a simple biological event, nor a philosophical event that shows a major breakthrough in the understanding of self-direction.It is also a major economic event, a symbol of Tango's new economy generation. After hundreds of thousands of years of hunting and gathering economy, human society has entered the era of agricultural economy for about 10,000 years.Britain was the first to enter the industrial economy in the 1860s, while the United States took the lead in completing the historical process of industrial economy in the 1950s and embarked on the road of information economy.According to expert analysis, the "lifespan" of this economic form is 75 to 80 years, and it will gradually lose its vitality in the 2020s.At that point, humanity will be ready for the next economic era:

bioeconomy. In 2020, "biology" will replace "information". In fact, we have already crossed the threshold of the bioeconomy.As early as 1953, Crick and Watson identified the DNA double helix structure, which opened the prelude to the bioeconomy. Rifkin said: Great economic changes in history have always occurred when multiple technological and social forces converged and created a new "operating framework".There are now 7 forces that constitute the operating framework of the biotechnology century.The gathering of these forces constitutes the framework of a new economic era.

First, the ability to isolate, identify, and recombine genes makes it possible to build gene banks and, for the first time ever, use them as a major resource for future economic activity.Recombinant DNA technology and other biotechnologies, in turn, enable scientists and biotechnology companies to find, manipulate and develop genetic resources according to specific economic needs. Second, since genes, cell lines, and genetically engineered tissues, organs, and organisms, as well as the processes used to modify them, can be patented, the exploitation of these new resources has been introduced to the market for commercial gain.

Thirdly, the internationalization of commerce and trade has made it possible to reseed the earth's bio-residues with the second "genesis" of the bio-industry, which is artificially produced by laboratory genetic breeding and aims to replace the natural evolutionary route.The global life sciences industry has begun to have an unprecedented impact on the planet's many biological resources.In the nascent biotech market, areas of the life sciences, from agriculture to medicine, are coalescing under the umbrella of large 'life' companies. Fourth, the mapping and sequencing of about 100,000 genes in the human genome, new breakthroughs in genetic screening, including DNA chips and somatic cell gene therapy, and the genetic engineering of human eggs, sperm and embryonic cells are all comprehensive Altering the human germline and paving the way for the birth of a business-driven eugenic society.

Fifth, a large amount of new scientific research based on the genetic basis of human behavior, and a new sociobiology that favors nature and underestimates education, all provide a cultural environment for the widespread acceptance of new biotechnology. Sixth, computers provide the tools for the management and exchange of genetic information that constitutes the biotech economy.Researchers around the world are using computers to decipher, retrieve, classify and organize genetic information, creating a new repository of genetic capital for the bioindustrial age.Computer technology and genetic technology are merging to create a new and powerful technological reality.

Seventh, the new cosmology of evolution, the new technology and the new world economy are not incompatible with nature, starting to challenge the neo-Darwinian camp.The new view is that the new ideas we use to reorganize our economies and societies are in fact extensions of nature's own principles and practices, and thus legitimate.These ideas provide a legitimate framework for the biotech century. The century of biotechnology has brought a new resource, a whole new set of technologies to transform humans and nature, new forms of commercial protection to stimulate trade, global reseeding of the products of artificial breeding through international trade markets, new science of eugenics, new Sociology, new communication tools for organizing and managing economic activity at the genetic level, new cosmology, etc.In short, genes, biotechnology, patents on life, the global life science industry, the screening and repair of human genes, new cultural trends, computers, and revisions to the theory of evolution, etc., are beginning to reshape our world.

At the heart of the new genetic engineering revolution, Rifkin believes, is efficiency and speed.Natural production and circulation are no longer sufficient to improve the living standards of an ever-increasing population.To compensate for nature's slow pace, new ways must be discovered to engineer the genetic blueprints of microbes, animals and plants, and accelerate their transformation into valuable commercial products.The designed genetic blueprint can make trees grow faster; processing genetic instructions can transform local livestock breeds into fast-growing "super animals"; redesigning the genetic information of food crops can increase food production.A study by the US government's (now defunct) Office of Technology Assessment found that bioengineering "could play a major role in improving the speed, efficiency and productivity of biological systems".Our ultimate goal is to produce biological materials at a rate that far exceeds the natural growth laws, and convert them into economic resources with a growth curve that rivals the industrial age.

Perhaps some historians may argue that humans have been concerned with improving the quality and growth rate of biological resources as early as the early Neolithic, when agriculture was the way of life.Even so, we still have reasons to believe that genetic engineering does not simply change biological resources in terms of degree but in nature, and changes and reorganizes our relationship with the biological world conceptually, although the motivation behind genetic engineering can be traced back to ancient times era, but the technology itself has many new properties.To understand this further, we must identify the difference between traditional tinkering and manual techniques and modern genetic engineering.

Humans have domesticated, bred and hybridized animals and plants for more than 10,000 years.However, in the long history of such practices, the boundaries of biological species in nature have always constrained and limited human behavior.Although nature occasionally allows us to cross biological species boundaries, such crossings are always strictly limited.Hybrids of animals are usually sterile (like mules), while hybrids of plants are not truly pure.As the famous horticulturalist Burbank (LushanerBllrbank) and many of his pioneers realized, when various improvement efforts are carried out at the level of organisms or living species, there are certain inherent limitations. factor constraints.

Genetic engineering transcends the limits of all living species boundaries.Its processing of organisms is not at the species level but at the gene level. The operating unit is no longer an organism but a gene, and the significance brought about by this is very far-reaching and extensive. First, as we recombine genetic traits across natural biological mating boundaries, the whole notion of species as distinct and separately identifiable entities becomes an obsolete proposition.Here are three examples of how genetic programming is causing dramatic changes in our relationship with nature. In 1983, Rfor Brinster of the School of Veterinary Medicine at the University of Pennsylvania introduced the human growth hormone gene into mouse embryos and made it express, so that the growth speed and volume of mice were twice that of other mice.These "super mice" also passed on their human growth-promoting Qin gene to their offspring.One strain of mice, after several generations of economic transmission, survives today and continues to express the human ghrelin gene.This human gene has been permanently fitted into the genetic makeup of these animals.

In 1984, scientists in England fused sheep and goat embryonic cells and implanted them into surrogate animals, so that the surrogate animals produced sheep-goat chimeras.In human history, this is the first time that two completely unrelated animal species have successfully "fused". In 1986, scientists introduced the isolated firefly light-emitting gene into the genetic code of tobacco plants, and the tobacco leaves glowed accordingly. Such results cannot be achieved even with the most sophisticated conventional breeding techniques.But in a biotechnology laboratory, almost any kind of genetic recombination is possible.New genetic technologies allow us to cross the boundaries of nature, combine genetic material, and convert all life into craftable chemical materials.This new way of making creatures changes our relationship with nature.We began to see life from the perspective of a chemist, and organisms no longer commanded our attention or respect. Our view of, and interest in, nature increasingly focuses on the thousands of chemical components that make up the genetic blueprint of an organism. With our new ability to recognize, store and manipulate the chemical blueprints of our organisms, we will take on new roles in nature.Since the beginning of the world, we are the first engineers to make life.We begin to reprogram the mortal code of our organisms to suit cultural and economic needs or desires.We have undertaken the mission of the second "Genesis". This is a century of synthetic creations, designed to meet the demands of high efficiency and productivity. Facing the biotechnology revolution taking place around us and the coming biotechnology world, China has no other choice. It cannot wait, avoid, or miss.We can only greet, we can only grasp, we can only strive to catch up with the pace of the times. According to reports, at present, the world is spending hundreds of millions of dollars to find markers and identify the genes and their functions of various organisms in the biosphere. A large amount of genetic information of plants, animals and humans has been collected and stored. Within the Genome Database, as the primary primary resource for the coming century of biotechnology. Pioneering biotechnology are hundreds of new bioengineering companies such as Divan, Oreqenesls, Genzpoe, Calg6ne, Mmp, and Myriad Corporation, which are paving the way for the second greatest technological revolution in history.Dozens of large multinational companies including Du Pout, NOVartis, Up-john, Monsanto, Eli Lilly, Robin and has and M Chenucal have also invested a lot of money in biotechnology research. According to reports, almost every field of life sciences is actively formulating development guidelines.Long-term plans to renew equipment and recruit personnel are in full swing, with the aim of preemptively introducing new genetic commodities into the economy and preparing civilized society to taste the first fruits of the biotechnology era. In the United States alone, there are now 1,300 biotech companies with annual revenues of $13 billion and more than 100,000 employees.All of this is just the progress made in the first 10 years of an economic and technological revolution that is still centuries away.Nobel Laureate in Chemistry, Roben F. Curd of Rice University in the United States once announced to many of his scientific colleagues: "The 20th century is the century of physics and chemistry, and the 21st century will undoubtedly be the century of biology." New biotechnologies are already reshaping virtually every field. The Chinese government and enterprises must be aware of such a transformation and develop China's bio-economy with advanced awareness. Although China does not have as much capital and less natural resources per capita than others, China has more professionally trained people and more intellectual resources, which are our advantages in developing the bio-economy. As the technologies for transforming life become more mature, and the human genome is more thoroughly interpreted, various forward-looking technologies are moving towards biotechnology products. "Gene" has unlimited potential business opportunities and benefits.Some pharmaceutical companies have successfully used recombinant genetic engineering technology to manufacture high-priced drugs, such as human growth hormone (hGH) for dwarfism, erythropoietin (EPO) for anemia, and human tissue cells for emergency treatment of heart attacks. Plasma plasmogen activator (tPA) and insulin for the treatment of diabetes, etc., these drugs have created a market value of 13 billion US dollars in annual sales (estimated value in the United States in 1995). Genes are money.Genes are wealth.Genes are the new source of wealth. Genes are the source, growth point and commanding heights of the biopharmaceutical industry, and technological expansion derived from genes will be the basis for developing new products for century pharmaceutical companies.With the progress of the "Human Genome Project", more genome industries have emerged and will emerge, and their prospects are much greater than those of color TVs, refrigerators, automobiles and even computers.Bill Gates said that the next person to create greater wealth will appear in the field of genes. At present, major pharmaceutical, chemical and agricultural companies in the world are actively reorganizing, merging and establishing new alliances in order to strengthen their competitiveness through gene-related research and development.All pharmaceutical companies in the United States invest in this.As soon as Siquark Therapeutics announced that it had cloned the asthma gene, the stock price rose many times.Parents in the United States, in order to make their short children grow taller, inject their children with a growth hormone gene drug, which costs 50,000 US dollars a year for 5 consecutive years. There are two small examples of obtaining wealth through genes.According to reports, many years ago, scientists discovered a rare perennial corn strain that grew in the mountain forests of southern Mexico.Only a few thousand of the perennial corn strains grew on three tiny plots of land when farmers and loggers were preparing to bulldoze them.This new corn strain was later found to be resistant to the leaf dieback fungus.Leaf dieback fungus was once a serious disaster for corn in the United States, costing farmers more than $2 billion that year.Geneticists and experts at breeding companies estimate the commercial value of the newly discovered strain of leaf-blight-resistant fungus could be worth billions of dollars a year. The rose-coloured periwinkle found in the rainforests of Madagascar is another vivid example of the potential commercial profits for genetic companies.A few years ago, researchers discovered a rare vinca plant with a unique genetic trait that could be used as a medicine to treat certain cancers. Eli Lilly Pharmaceuticals is developing it into a drug and is making huge profits -- $160 million in sales in 1993 alone. In addition to obtaining wealth through production and processing based on genetic technology, obtaining relevant patents is also an important source. Obtaining a patent or right to use a particular cell line or gene is likely to bring great commercial returns in the future. AMGE, in 1997, transferred a gene related to diseases of the central nervous system, making a net profit of 392 million US dollars.Rockefeller University, for patenting an obesity gene, has so far received $140 million. Reporter Mark analyzed: The basis of the gene industry is genetic resources, and genes are limited. If one is discovered, one is missing, and whoever discovers it first can apply for a patent, and latecomers have to pay high patent royalties if they want to use it.Just as the value of gold, silver, copper, iron, oil and coal is different, so is the value of genes.Some genes determine a person's tall, short, fat, thin, handsome and ugly, and some determine a person's life, old age, sickness, and death temperament. Whoever applies for a gene patent with high economic value, such as an anti-AIDS gene, will have to consider how to spend the money next. CELERA has the power of a lion and the greed of a dog. It even wants to apply for a patent on the human genome sequence map. This attempt to deprive others of mining rights has been strongly resisted by governments and the mainstream scientific community from beginning to end. Scientists involved in the Human Genome Project Adopting the method of completing batches of announcements makes it impossible for CELERA to apply for a patent. In order to compete with CELERA, the completion time of the Human Genome Project was advanced from 2005 to June 2001. However, the final discovery of genes can still be patented, and CEIJZRA and other multinational companies have been racing against time to invest in the gene patent war. According to Rifkin: In recent years, companies have rushed to apply for human genome patents, showing a strong upward momentum, largely because people are rapidly determining and mapping the approximately 100,000 genes that make up the human genome. Often, the "discoverer" applies for a patent immediately after the gene sequencing is completed, and is often busy applying for a patent even before the function or role of the gene is known. In 1991, Venter (Ctalg Venter), then a subject leader of the NIH Human Genome Research Project, resigned from the government and joined a genome company invested by venture capitalists with more than 70 million US dollars.At the same time, Venter and his colleagues applied for patents on more than 2,000 human brain genes.Many researchers working on the Human Genome Project were shocked and outraged, accusing Venter of attempting to profit financially from the results of research funded by US taxpayers.Some of these scientists were outraged because Venter rushed to patent the genes before they even knew what they were supposed to do.Dr James Watson, Nobel laureate, co-discoverer of the double helix structure of DNA and former leader of the Human Genome Project, called it "absolute insanity".But Venter, along with many other scientists and genome companies, continued avidly to pursue his goal of patenting as many human genomes as possible.It is expected that in less than 10 years, about 100,000 genes bequeathed to us humans will all be protected by patents and become pharmaceuticals and chemicals.Exclusive intellectual property for agricultural and biotech companies.Bring huge wealth to the patent owner. When it comes to genes and wealth, one cannot fail to talk about stocks. In the United States, investors flocked to buy shares of the first genetic engineering company to go public. One million shares of Gentech were listed at $35 a share, and within 20 minutes of the market opening, the stock shot up to $89 a share.By the time the stock market closed in the afternoon, this fledgling biotechnology company had raised $36 million, and its asset valuation had reached $532 million.Shockingly, the company didn't have a single product on the market.A market analysis expert said: "I have worked in (Merrill Lynch Investment Corporation) for 22 years, and I have never seen this kind of thing happen." Celera, which was just established in May 1998, is a gene company that competes with the Human Genome Project and is a data leader. Its stock price has surpassed that of Microsoft, which is indeed worthy of attention. As scientists announced that the draft of the human gene code has been completed, dozens of start-up genetic engineering companies are currently actively developing various functions of genes, and trying to take advantage of this "gene fever" to go public and raise funds.At present, Wall Street has set off a wave of public offerings of shares of genetic companies. Since the beginning of this year, 8 biotechnology or gene-related companies have been officially listed, and their stock prices have performed well.Another as many as 17 genetic companies are scheduled to go public within this year.According to the statistics of New York Investment Research Company, the 8 genetic engineering companies listed so far have raised a total of 840 million US dollars. The current stock prices are all above the issue price, and the trend is stable, which makes the underwriters excited.Entrepreneurs of these gene companies and Wall Street stock underwriters are using the old routines of biotechnology companies in the early 1990s and Internet companies in the past two years to raise funds when they go public: seize the hot spots in the stock market and take advantage of the momentum. China's stock market has been stimulated by such great benefits, and the "gene sector" has also seen impressive gains.People are thinking about the myth of Internet stocks, and hope that the gene bio stock can continue to write the "Internet myth".Whether it can be continued, let's look at Mr. Hu Peng's point of view: It should be admitted that today's bio-industry cannot compare with the information industry in terms of development speed, scale, or confidence.The impact of the Human Genome Project on ordinary people is far less than that of the Internet, just as the Internet in the 1970s cannot be compared with the power grids and railways that spread all over the world at that time. But just last month, the Nasdaq plunged 25% in a week, shocking the world and prompting reflections on the bubble in the exploding internet market.Just as Internet stocks shrank and entered a painful adjustment stage, biological stocks rose steadily. Still taking Celera as an example, Microsoft, Amazon and other companies can only be amazed if they fight against the International Human Genome Project on their own.It's no wonder that, although the shares of Celera were severely setback after Clinton and Blair's speeches calling for the disclosure of genome information, they soon rose, and its market value was dozens of times that of when it was first established. Some people say that the Human Genome Project is the "Holy Grail" of life sciences and the runway for biotechnology to take off in the 21st century. The genome project only obtains genetic sequences, but it is the premise of comprehensively searching for valuable genetic information.Professor Yu Jun, deputy director of the Human Genome Center of the Institute of Genetics, Chinese Academy of Sciences, couldn't be more accurate: "Our sequencing work is compiling a dictionary, which is for writing articles in the future." The distance from "literacy" to "writing articles" How far it is is hard to say.But biologists are convinced that with the "dictionary" and their creativity, excellent works will be produced one after another. In a few years, the biological industry will become the new spokesperson of the new economy. Some people say that the Internet does not generate wealth, it only saves wealth, and the future biological industry can create real wealth. Both the information industry and the biological industry are undoubtedly products of high technology, but in terms of wealth creation, it can be said that the former "cuts expenditure" and the latter "open source".In this sense, biologists can compose more wonderful "biological myths". How will today's genome projects change our future?How do biologists compose a new version of the "network myth"? Professor Fant's words are the best answer: "The significance of deciphering the genome code is like that in the era when electricity was just discovered, no one could imagine a personal computer." The prospect of biological stocks is attractive, but why are the biological stocks on the Chinese stock market suddenly warm and cold?He Xiaoqing attributed it to three reasons: First of all, the completion of the drawing of the working draft of the human genome is only the beginning of a genetic revolution in human biology, and there is still a long way to go for companies to realize their commercial value.Just as the computer network has brought revolutionary changes to the human economy and society, the biotechnology revolution initiated by HGP will also bring unlimited business opportunities to the global economy.But experts believe that it will take at least another two years to complete the genome map that has been repeatedly verified.Even at that time, the technological gap cannot be filled with the current technology, or in other words, there are more problems that humans cannot grasp for a while, and they need to be overcome by the next generation, which may take 100 years to complete.Of course, it is not ruled out that the commercial value of the obtained research results can be developed, but the development of the gene technology industry requires a good mechanism for transformation of achievements, venture capital, and talent incentives. In these aspects, there is still a big gap in our country. Secondly, China's biopharmaceuticals are still in their infancy and are in capital investment.New drug development capability, technical level and industrialization degree are far behind some developed countries, and the utilization of HGP research results is no exception.During my country's "Ninth Five-Year Plan" period, the "863" plan, key research projects, and natural science foundations have a total annual expenditure of about 400-500 million yuan in the field of biotechnology and life sciences, which is still less than the annual R&D investment of a medium-sized company in the United States. In 1998, the output value of China's biotechnology drugs was less than 1 billion yuan. It is estimated that the output value of biotechnology drugs in 2000 could reach 4.5 billion yuan, but it still accounted for less than 3% of China's entire drug market.As for the development of new genetic drugs, it has just begun.These show that in the field of biopharmaceuticals related to gene research, our country is very weak in both technical and economic foundations, and lacks good conditions for the development of the gene industry. Third, there are not many biotechnology companies with real modern significance among the listed companies, and there are even rarer ones that can use the research results of HGP.It is undeniable that some listed companies with foresight have begun to devote themselves to the fields of biopharmaceuticals and genetic research.However, the "high threshold" of high investment and long payback time in gene technology has also made some listed companies feel overwhelmed. Some companies have set foot in the field of genes, but have not conducted serious feasibility studies, just trying to figure out a fashionable concept. They are stepping into After entering the genetic field, I realized how difficult it is to invest in the genetic industry. Not every listed company has strong technical capabilities and economic support. Grabbing the Genetic New World—A New Enclosure Movement Just as the control of fossil fuels and precious metals in the industrial age helps to control the international market, the economic and political forces that control the earth's genetic resources in the biotechnology era will have a great impact on the future world economy. big. Experts pointed out that in the coming years, the shrinking gene pool on the earth will become an asset that will continue to appreciate. Some multinational corporations and governments have guarded and searched for the "green gold" of the New World, hoping to discover the rare genetic characteristics of microorganisms, plant varieties and people with potential market in the future.Once a desired genetic trait is discovered, biotech companies can modify it and apply for a patent to protect their new "invention." Just like the enclosure movement in British history, a new enclosure movement—the private possession of genetic resources on the earth has begun in full swing.People's international efforts to transform the biological genetic blueprint that has evolved over millions of years into private intellectual property not only represents the completion of the 500-year history of commercialization, but also marks the end of the last public domain left by nature. Many large companies in developed countries conduct bioprospecting in developing countries, and then transform genetic resources into commodities that can be priced and marketed through methods such as modification and production of plant genetic makeup.This free-for-all commercial encroachment has aroused opposition from developing countries. Two typical characteristics of the biological industry are resource dependence and resource informatization.This makes biological resources a strategic resource that can be contested and reoccupied after land resources.The strategies and technologies developed by the Human Genome Project have transformed the biological resources from the original population germplasm resources to sequence and informationization, and made its protection more difficult.Scientists warn that if we don't realize this, our biological resources may be lost, the source of the biological industry will be lost, and biotechnology will become a meal without rice because there is no "resource gene".In fact, many large foreign companies are already vying for genetic resources in mainland China. In July 1997, Professor Tan Jiahui, a leading figure in Chinese genetics, wrote to the state leaders: "The loss of human genetic resources in our country is already very serious. If we do not take effective measures, our genetic resources will be plundered and exhausted, and we will soon become a foreign country. company's patent." Let’s take a look at a few examples of foreign companies scrambling to enter China’s genetic mainland: In January of this year, the US company Celera launched a large-scale operation to seize my country's genetic resources.In Taiwan, the company has received support from the political and business circles, and plans to invest US$100 million to establish Taiwan's biological gene resource sequence database.In Shanghai, the company acquired a 95% stake in Getw and publicly stated that "access to the diversity of plant, animal and human genetic resources, which is rich in China, is crucial to Celera's access to genetic information." China has a large population, many ethnic groups, and many types of diseases, and its genetic resources are indeed the richest in the world.Due to differences in ethnic cultural backgrounds and living habits, the genetically relatively isolated population is the largest and the most "pure"; in addition, the spectrum of diseases is particularly wide, including infectious diseases with high incidence in developing countries or certain genetic diseases, as well as those caused by lifestyle changes. The "disease of wealth" caused byTherefore, the genome samples of the Chinese population are not only rare materials for understanding human genetic diversity, but also a source for discovering disease-related genes.Celera is not the only one coveting China's genetic resources. In recent years, incidents related to the outflow of genetic resources have occurred from time to time. In 1997, the American "Science" magazine reported that the American company Siquana obtained the disease-causing gene of an asthmatic family in a mountain village in Zhejiang, and then publicized the value of the gene to achieve its commercial purpose.Unfortunately, we still don't understand how the Siquana Company stole the genes from this mountain village. Also in 1997, Harvard University launched a so-called "Population Genetics Project" to study various "diseases of affluence" including diabetes, high blood pressure, and obesity in China.Harvard University, under the guise of cooperative research with a domestic institution, "has the opportunity, right, and access" to use China's huge genetic resource pool.It is difficult to predict how much patent transfer fees we will have to pay for this in the future. In March 1998, funded by a foreign institution, under the name of "Monitoring the Health and Longevity of the Elderly", a blood collection activity was carried out for 10,000 elderly people in China.With the development of the activity, the people concerned exposed the truth, and at the same time wrote to the relevant units, requesting to stop the activity.Later, the opponents of the activity took the supporters to court and stopped the loss of genes of thousands of elderly people according to law.Relevant experts believe that under the guise of public welfare investigations, foreign organizations are trying to plunder the "longevity genes" of the elderly in China. Once these genes are lost to foreign countries, our future losses may reach tens of billions of dollars. In April 2000, the Ministry of Science and Technology announced a case of illegally carrying human genetic resource materials through customs and was seized.Without approval, Beijing Cai Biotechnology Co., Ltd. entrusted someone to carry slices of human tumor tissue and precious genetic resource materials in the tissue, in an attempt to break through customs and transport them abroad, but was seized by Beijing customs officers. (Zhao Yan: "Genetic New World") These shocking facts remind people that we must cherish our genetic resources. The new generation based on genetic technology is a severe test for every country, every enterprise and individual. It also presents an opportunity of unprecedented magnitude.Genetic wealth has similarities with traditional wealth, but also has new features.The same thing is that they all need to convert technology into commodities, both have patent disputes, and both have to occupy resources.But its patents and resources are not realized by everyone or enterprises.After patents and resources are occupied by a few people, many people may have nothing and be willing to be slaughtered.This is the peculiarity of genetic wealth.But once you have patents and unique resources, the river of wealth will overwhelm you. This is the cruelty and temptation of genetic wealth. In the face of genetic wealth, have you planned?